FOR IMMEDIATE RELEASE

Molecular Targeting Technologies, Inc. Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting

West Chester, PA, July 11, 2020 -- Molecular Targeting Technologies, Inc. (MTTI) is a clinical stage company creating innovative products to see and treat cancer. MTTI's platform includes EBTATE (^{177}Lu-DOTA-EB-TATE) to treat neuroendocrine tumors (NETs) and EBRGD (^{177}Lu-DOTA-EBRGD) to treat glioblastoma multiforme and non-small cell lung cancer.

MTTI announced today that four abstracts highlighting this therapeutic and two novel diagnostics were selected for oral and poster presentations at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Virtual Meeting, July 11 – July 14, 2020. The Presentations:

EBTATE

Oral Presentation 413

Peptide Receptor Radionuclide Therapy of Late-stage Neuroendocrine Tumor Patients with Multiple Cycles of ^{177}Lu-DOTA-EB-TATE

As neuroendocrine tumor (NET) incidence rates rise, an effective treatment option has never been more critical. ^{177}Lu-DOTA-EB-TATE (EBTATE) is a precision medicine that uses an Evans Blue moiety to increase albumin residence and prolong half-life. Early clinical trials showed improved safety and efficacy with fewer, lower doses than competing treatments. US-based trials are planned for early 2021.

EBRGD

Oral Presentation 349

First-in-Human Study of a ^{64}Cu-Labeled Long-Acting Integrin $\alpha_v\beta_3$ Targeting Molecule ^{64}Cu-NOTA-EB-RGD in Healthy Volunteers and GBM Patients

There is no effective treatment for Glioblastoma Multiforme (GBM). And few Non-Small Cell Lung Cancer (NSCLC) patients respond effectively to chemo- and immunotherapies. MTTI is developing ^{177}Lu-EBRGD, a radiotherapeutic targeting $\alpha_v\beta_3$ integrin overexpressing tumors, bound to an Evans Blue moiety to prolong circulation and increase tissue residence.

In early clinical trials ^{64}Cu-NOTA-EB-RGD (^{64}Cu-EBRGD) , a new, relatively long-lived PET tracer showed diagnostic efficacy in patients with glioblastoma. It is a superior, high-contrast imaging diagnostic in patients, visualizing tumors with low or moderate levels of integrin, with high sensitivity. This confirms

EBRGD targeting and persistent presence on the tumor. US-based Phase I trials of our ^{177}Lu-DOTA-EBRGD therapeutic are planned for 2021.

FGA

Poster 1229

Assessment of ^{18}F-fluoroglucarate uptake in lung and brain cancer cell lines

Poster 1220

Effect of fructose and glucarate on ^{18}F-Fluoroglucarate uptake in cancer cells

Poster 228

Evaluation of ^{18}F-FGA PET/CT for specific imaging of necrotic tissue in a mouse model of coronary artery ligation

Radiolabeled glucaric acid, a marker for histones associated with cell death, images tumor response to therapy, several types of cancer, acute MI and stroke. ^{18}F-Fluoroglucaric Acid (FGA) clearly distinguishes different levels of necrosis, potentially preferred over FDG for detection of tumor response to therapy using PET/CT imaging. It provides reliable diagnostic results in as little as one day.

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of disease.

More information: www.mtarget.com ; Contact: Chris Pak, **Email: cpak@mtarget.com ; Ji Li, Email: jli@mtarget.com ; Tel: (610) 738-7938**